197 related articles for article (PubMed ID: 36044839)
21. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies.
Marsh V; Davies EJ; Williams GT; Clarke AR
J Pathol; 2013 Jun; 230(2):165-73. PubMed ID: 23483557
[TBL] [Abstract][Full Text] [Related]
22. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
Tannapfel A; Sommerer F; Benicke M; Katalinic A; Uhlmann D; Witzigmann H; Hauss J; Wittekind C
Gut; 2003 May; 52(5):706-12. PubMed ID: 12692057
[TBL] [Abstract][Full Text] [Related]
23. Single-PanIN-seq unveils that
Liu S; Cao W; Niu Y; Luo J; Zhao Y; Hu Z; Zong C
Elife; 2021 May; 10():. PubMed ID: 33983114
[TBL] [Abstract][Full Text] [Related]
24. The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma.
Wang J; Ge F; Yuan T; Qian M; Yan F; Yang B; He Q; Zhu H
Expert Opin Ther Targets; 2022 Sep; 26(9):781-789. PubMed ID: 36243001
[TBL] [Abstract][Full Text] [Related]
25. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
[TBL] [Abstract][Full Text] [Related]
26. Establishment and characterisation of six human biliary tract cancer cell lines.
Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
[TBL] [Abstract][Full Text] [Related]
27. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
28. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.
Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U
J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786
[TBL] [Abstract][Full Text] [Related]
29. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice.
Kimura Y; Fukuda A; Ogawa S; Maruno T; Takada Y; Tsuda M; Hiramatsu Y; Araki O; Nagao M; Yoshikawa T; Ikuta K; Yoshioka T; Wang Z; Akiyama H; Wright CV; Takaori K; Uemoto S; Chiba T; Seno H
Gastroenterology; 2018 Jul; 155(1):194-209.e2. PubMed ID: 29604291
[TBL] [Abstract][Full Text] [Related]
30. Mutational landscape of intrahepatic cholangiocarcinoma.
Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H
Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346
[TBL] [Abstract][Full Text] [Related]
31. Involvement of c-Ski oncoprotein in carcinogenesis of cholangiocacinoma induced by Opisthorchis viverrini and N-nitrosodimethylamine.
Boonmars T; Wu Z; Boonjaruspinyo S; Puapairoj A; Kaewsamut B; Nagano I; Pinlaor S; Yongvanit P; Wonkchalee O; Juasook A; Sudsarn P; Srisawangwong T
Pathol Oncol Res; 2011 Jun; 17(2):219-27. PubMed ID: 20853076
[TBL] [Abstract][Full Text] [Related]
32. Mouse Model for Cholangiocarcinoma from Peribiliary Glands.
Nakagawa H; Suzuki N; Koike K
Methods Mol Biol; 2019; 1905():237-245. PubMed ID: 30536105
[TBL] [Abstract][Full Text] [Related]
33. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
Tessiri S; Techasen A; Kongpetch S; Namjan A; Loilome W; Chan-On W; Thanan R; Jusakul A
PeerJ; 2022; 10():e12750. PubMed ID: 35070505
[TBL] [Abstract][Full Text] [Related]
35. Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21.
Kawamura E; Matsubara T; Daikoku A; Deguchi S; Kinoshita M; Yuasa H; Urushima H; Odagiri N; Motoyama H; Kotani K; Kozuka R; Hagihara A; Fujii H; Uchida-Kobayashi S; Tanaka S; Takemura S; Iwaisako K; Enomoto M; Taguchi YH; Tamori A; Kubo S; Ikeda K; Kawada N
FEBS Open Bio; 2022 Dec; 12(12):2122-2135. PubMed ID: 36114826
[TBL] [Abstract][Full Text] [Related]
36. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
37. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
[TBL] [Abstract][Full Text] [Related]
38. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
39. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
40. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.
Xu X; Kobayashi S; Qiao W; Li C; Xiao C; Radaeva S; Stiles B; Wang RH; Ohara N; Yoshino T; LeRoith D; Torbenson MS; Gores GJ; Wu H; Gao B; Deng CX
J Clin Invest; 2006 Jul; 116(7):1843-52. PubMed ID: 16767220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
